Working… Menu

Compassionate Use of REGN-COV2 for the Treatment of COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04617535
Expanded Access Status : Available
First Posted : November 5, 2020
Last Update Posted : November 5, 2020
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:
Provide Compassionate Use access to REGN-COV2 for adult patients with recently diagnosed mild-to-moderate coronavirus disease (COVID-19) who are at high risk for poor outcomes.

Condition or disease Intervention/treatment
Covid19 Drug: REGN10933+REGN10987 combination therapy

Detailed Description:
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: REGN10933+REGN10987 combination therapy
    Administered intravenously (IV) single dose

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04617535

Layout table for location contacts
Contact: Requests for compassionate use must be initiated by a treating physician. Physicians should contact 844-734-6643

Sponsors and Collaborators
Regeneron Pharmaceuticals
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals Identifier: NCT04617535    
Other Study ID Numbers: R10933-10987-COV
First Posted: November 5, 2020    Key Record Dates
Last Update Posted: November 5, 2020
Last Verified: November 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases